1) Lijun Zhao†, Shuhong Li†, Xiaoyi Wei, Xuexiu Qi, Qiaoru Guo, Licai Shi, Ji-Shuai Zhang, Jun Li, Ze-Lin Liu, Zhi Guo, Hongyu Zhang, Jia Feng, Yuanyuan Shi, Suping Zhang,Yu J. Cao*, A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignances, Protein & Cell, 2024, Jun 1; Online ahead of print. PMID: 38823002.
2) Qiao-ru Guo,Yu J. Cao*, Applications of genetic code expansion technology in eukaryotes, Protein & Cell, 2024 May 7;15(5):331-363. PMID: 37847216.
3) Dong Liu†, Xuexiu Qi†, Xiaoyi Wei, Lijun Zhao, Xuechun Wang, Shuhong Li, Zhidong Wang, Lisai Shi, Jie-an Xu, Mei Hong, Zhong Liu, Lili Zhao*, Xiankun Wang, Bo Zhang, Yuhan Zhang, Feng Wang,Yu J. Cao*,A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy, Theranostics, 2022, Nov 14;12(18):7788-7803. PMID: 36451856.
4) Lijun Zhao, Shuhong Li, Xiaoyi Wei, Xuexiu Qi, Dong Liu, Lei Liu, Feiqiu Wen, Ji-shuai Zhang, Feng Wang, Ze-lin Liu*,Yu J. Cao*, A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL, Blood, 2022 Oct 20; 140(16): 1790-1802. PMID: 35981465.
5) Yu J. Cao*,†, Chenfei Yu†, Kuan-Lin Wu†, Xuechun Wang, Dong Liu, Zeru Tian, Lijun Zhao, Xuexiu Qi, Axel Loredo, Anna Chung, Han Xiao*. Synthesis of precision antibody conjugates using proximity-induced chemistry, Theranostics, 2021, Aug 27; 11(18):9107-9117. PMID: 34522229.
6) Yu J. Cao*, Xuechun Wang, Zhidong Wang, Lijun Zhao, Shuhong Li, Zhuxia Zhang, Xiaoyi Wei, Hwayoung Yun, Sei-hyun Choi, Zhong Liu, Lili Zhao, Stephanie A. Kazane. Switchable CAR-T Cells Outperformed Traditional Antibody-Redirected Therapeutics Targeting Breast Cancers, ACS Synthetic Biology, 2021, May 21; 10(5):1176-1183. PMID: 33856201(Research Highlight in Nature Chemical Biology).
7) Zhidong Wang,Yu J. Cao*. Adoptive cell therapy targeting neoantigens: a frontier for cancer research, Frontiers in Immunology, 2020, Mar 5; 11: 176-188. PMID: 32194541.
8) Lijun Zhao,Yu J. Cao*. Engineered T Cell Therapy for Cancer in the Clinic, Frontiers in Immunology, 2019, Oct 11; 10: 2250-2269. PMID: 31681259.
9) Yuhan Zhang, Changming Fang, Rongsheng E. Wang, Ying Wang, Hui Guo, Chao Guo, Lijun Zhao, Shuhong Li, Xia Li, Peter G. Schultz*,Yu J. Cao*, Feng Wang*. A tumor-targeted immune checkpoint blocker, Proceedings of the National Academy of Sciences, 2019, Aug 6; 116(32):15889-15894. PMID: 31332018.
10) Lawrence H. Cheung, Yunli Zhao, Ana Alvarez-Cienfuegos, Khalid A. Mohamedali,Yu J. Cao, Walter N. Hittelman, Michael G. Rosenblum. Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B, Journal of Experimental & Clinical Cancer Research, 2019, Jul 30; 38(1): 332-345. PMID: 31362764.
